Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Other Accumulated Expenses (2019 - 2025)

Historic Other Accumulated Expenses for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $1.3 million.

  • Legend Biotech's Other Accumulated Expenses fell 9923.21% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 9923.21%. This contributed to the annual value of $532000.0 for FY2024, which is 9956.5% down from last year.
  • According to the latest figures from Q3 2025, Legend Biotech's Other Accumulated Expenses is $1.3 million, which was down 9923.21% from $138.8 million recorded in Q2 2025.
  • Legend Biotech's 5-year Other Accumulated Expenses high stood at $184.1 million for Q4 2022, and its period low was $80096.0 during Q1 2021.
  • For the 5-year period, Legend Biotech's Other Accumulated Expenses averaged around $105.8 million, with its median value being $123.6 million (2021).
  • As far as peak fluctuations go, Legend Biotech's Other Accumulated Expenses skyrocketed by 12870584.48% in 2021, and later crashed by 9956.5% in 2024.
  • Legend Biotech's Other Accumulated Expenses (Quarter) stood at $123.6 million in 2021, then skyrocketed by 49.01% to $184.1 million in 2022, then tumbled by 33.57% to $122.3 million in 2023, then plummeted by 99.57% to $532000.0 in 2024, then surged by 137.97% to $1.3 million in 2025.
  • Its Other Accumulated Expenses stands at $1.3 million for Q3 2025, versus $138.8 million for Q2 2025 and $116.8 million for Q1 2025.